Lupin launches generic Desoximetasone Topical Spray, 0.25% in the US

It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older

Pharma major Lupin announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.’s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

Desoximetasone Topical Spray, 0.25% had annual sales of approximately USD 18.7 million in the US.